Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Elorac to Present Naloxone Lotion Phase III Study Update
Details : The Phase III SPIRIT-2 trial is evaluating the safety and efficacy of naloxone lotion for relief of pruritus (itching) associated with Cutaneous T-Cell Lymphoma .
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 02, 2020
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The availability of naloxone lotion within the current Phase 3 study offers potential relief to people living with cutaneous T-cell lymphoma whose quality of life is significantly impaired by chronic, unrelenting itching.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 10, 2020
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable